Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 5/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369574 | 0.96 | POLB (0.51) | POLBHSD17B10SIGMAR1MEN1KMT2A | |
| SCHEMBL22208127 | 0.92 | POLB (0.46) | POLBHSD17B10SIGMAR1MEN1KMT2A | |
| SCHEMBL4702651 | 0.89 | POLB (0.45) | POLBHSD17B10SIGMAR1HRH3 | |
| SCHEMBL3272642 | 0.84 | SIGMAR1 (0.51) | POLBHSD17B10SIGMAR1MEN1KMT2A | |
| SCHEMBL3272638 | 0.84 | SIGMAR1 (0.51) | POLBHSD17B10SIGMAR1MEN1KMT2A | |
| SCHEMBL22191535 | 0.84 | SIGMAR1 (0.48) | POLBHSD17B10SIGMAR1MEN1KMT2A | |
| SCHEMBL15190856 | 0.84 | SIGMAR1 (0.51) | POLBHSD17B10SIGMAR1MEN1KMT2A | |
| SCHEMBL21847058 | 0.83 | ALDH1A1 (0.46) | POLBHSD17B10SIGMAR1 | |
| SCHEMBL4442585 | 0.83 | EPHX1 (0.47) | POLBHSD17B10SIGMAR1ACKR3CHRM5 | |
| SCHEMBL854472 | 0.83 | HTR4 (0.45) | POLBHSD17B10SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | POLB 1763/4885HSD17B10 2865/4885SIGMAR1 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.